Bevacizumab for pediatric radiation necrosis

BACKGROUND: Radiation necrosis is a frequent complication occurring after the treatment of pediatric brain tumors; however, treatment options remain a challenge. Bevacizumab is an anti-VEGF monoclonal antibody that has been shown in small adult cohorts to confer a benefit, specifically a reduction i...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Neurooncol Pract
Glavni autori: Baroni, Lorena V, Alderete, Daniel, Solano-Paez, Palma, Rugilo, Carlos, Freytes, Candela, Laughlin, Suzanne, Fonseca, Adriana, Bartels, Ute, Tabori, Uri, Bouffet, Eric, Huang, Annie, Laperriere, Normand, Tsang, Derek S, Sumerauer, David, Kyncl, Martin, Ondrová, Barbora, Malalasekera, Vajiranee S, Hansford, Jordan R, Zápotocký, Michal, Ramaswamy, Vijay
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2020
Teme:
Original Articles
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7393279/
https://ncbi.nlm.nih.gov/pubmed/32765892
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/nop/npz072
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items